Aventis Arava Liver Toxicity Warning Is Satisfactory, FDA Arthritis Cmte. Says
Executive Summary
Aventis' existing labeled warnings for Arava regarding liver toxicity do not need to be strenghened, members of FDA's Arthritis Advisory Committee told the agency at its March 5 safety review of the arthritis drug
You may also be interested in...
FDA Looked To Arava’s Safety Experience In Gauging Aubagio’s Risks
Agency’s assessment of teriflunomide for multiple sclerosis incorporated the known safety data for leflunomide, a chemically related drug with an extensive post-marketing record in rheumatoid arthritis. Despite hepatotoxicity and other safety concerns with the older drug, its clinical experience provided reassurance that Aubagio’s risks could be managed without a REMS.
CDER Dispute Resolution Policy Will Test “Ad Hoc” Arbitration
FDA's Center for Drug Evaluation & Research will run a one-year test of a formal dispute resolution process to resolve differences of opinion among reviewers
CDER Dispute Resolution Policy Will Test “Ad Hoc” Arbitration
FDA's Center for Drug Evaluation & Research will run a one-year test of a formal dispute resolution process to resolve differences of opinion among reviewers